Shares of Gilead Sciences Inc. rallied 2.83% to $110.67 Friday, on what proved to be an all-around great trading session for ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Best Value Stocks to Buy According to Billionaires. The company ...

Buying $1000 In GILD: If an investor had bought $1000 of GILD stock 20 years ago, it would be worth $9,708.95 today based on a price of $111.70 for GILD at the time of writing.

(Reuters) -Shares of Gilead rose 3% after the U.S. Supreme Court on Friday upheld a federal mandate that requires health ...

Gilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced that they have entered ...

As Gilead Sciences gets underway with the key launch of its twice-yearly pre-exposure prophylaxis (PrEP) HIV med, the company ...

Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers ...

Gilead Sciences has entered into an option and license deal with Kymera Therapeutics to support the development and sales of ...

Gilead Sciences (NASDAQ:GILD) has demonstrated a strong performance this year, with its stock up 18% compared to the S&P 500’s modest 2% gain.

Gilead Sciences Inc. closed 11.70% below its 52-week high of $119.96, which the company achieved on March 10th.

Gilead Sciences Inc. closed 11.48% below its 52-week high of $119.96, which the company reached on March 10th.

Gilead Sciences shows strong Q1 execution, pipeline momentum, and margin upside, led by HIV and PrEP launches. See why GILD stock is a strong buy.